CG Oncology, Inc. Common stock (CGON) Stock Price

CGONStock

$78.95+190.66%52W

Market Cap$7.00B

P/E—

PEG Ratio—

Div yield—

Beta0.20

CGON Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)30.45%

Price vs S&P 500 (4W)4.67%

VGM Score63.08

Book Value / Share (Quarterly)$11.65

P/TBV (Annual)4.45x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)176.56%

Cash Flow / Share (Quarterly)$-2.03

Price vs S&P 500 (YTD)76.46%

Gross Margin (TTM)-85.20%

Net Profit Margin (TTM)-3602.68%

EPS (TTM)$-2.70

10-Day Avg Trading Volume0.78M

EPS Excl Extra (TTM)$-2.70

EPS (Annual)$-2.08

ROI (Annual)-21.31%

Gross Margin (Annual)-15.02%

Net Profit Margin (5Y Avg)-10844.39%

Cash / Share (Quarterly)$11.64

Revenue Growth QoQ (YoY)1982.69%

ROA (Last FY)-20.34%

Revenue Growth TTM (YoY)1030.31%

EBITD / Share (TTM)$-3.03

ROE (5Y Avg)-23.98%

Operating Margin (TTM)-4056.18%

Cash Flow / Share (Annual)$-1.64

P/B Ratio6.43x

P/B Ratio (Quarterly)6.09x

Net Income / Employee (Annual)$-1,133,800

EV / Revenue (TTM)1060.64x

Net Interest Coverage (TTM)-35442.00x

ROA (TTM)-23.98%

EPS Incl Extra (Annual)$-2.08

Current Ratio (Annual)24.63x

Quick Ratio (Quarterly)21.78x

3-Month Avg Trading Volume0.99M

52-Week Price Return190.66%

Revenue / Employee (TTM)$43,900

Tangible BV / Share (Quarterly)$11.65

P/S Ratio (Annual)1639.19x

Asset Turnover (Annual)0.01x

52-Week High$80.97

Operating Margin (5Y Avg)-12109.07%

EPS Excl Extra (Annual)$-2.08

26-Week Price Return41.70%

Quick Ratio (Annual)24.09x

13-Week Price Return21.12%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)22.22x

Enterprise Value$6.61B

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$28,500

Pretax Margin (Annual)-3985.02%

Cash / Share (Annual)$9.20

3-Month Return Std Dev51.08%

Net Income / Employee (TTM)$-1,580,100

ROE (Last FY)-21.39%

EPS Basic Excl Extra (Annual)$-2.08

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.70

ROI (TTM)-25.12%

P/S Ratio (TTM)1063.31x

Pretax Margin (5Y Avg)-10844.39%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$9.32

Price vs S&P 500 (52W)172.35%

Year-to-Date Return88.42%

5-Day Price Return2.54%

EPS Normalized (Annual)$-2.08

ROA (5Y Avg)-20.45%

Net Profit Margin (Annual)-3985.02%

Month-to-Date Return9.89%

EBITD / Share (Annual)$-2.45

Operating Margin (Annual)-4722.13%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-21.56%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.70

P/TBV (Quarterly)6.09x

P/B Ratio (Annual)4.45x

Pretax Margin (TTM)-3602.68%

Book Value / Share (Annual)$9.33

Price vs S&P 500 (13W)18.32%

Beta0.20x

Revenue / Share (TTM)$0.07

ROE (TTM)-25.20%

52-Week Low$25.25

vGradeF

gGradeA

mGradeA

vgmGradeB

CGON Earnings Surprise History

Q2 25-0.54est. -0.45

Q3 25-0.57est. -0.55

Q4 25-0.51est. -0.58

Q1 26-0.71est. -0.54

Q2 26-0.90est. -0.64

CGON Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.19

4.14

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About CG Oncology, Inc. Common stock

CG Oncology is a late-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy for non-muscle-invasive bladder cancer. The candidate is in two Phase 3 trials targeting BCG-unresponsive and intermediate-risk patients, along with a Phase 2 study combining the therapy with checkpoint inhibition. The treatment aims to offer a bladder-sparing alternative to surgery for qualifying patients.